National Institute of Oncology

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with <i>PIK3CA</i>-mutated, HR-positive, HER2-negative advanced breast cancer who had rec...

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

The addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, ...

Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer

Among patients with high-risk, HER2-negative early breast cancer and germline <i>BRCA1</i> or <i>BRCA2</i> pathogenic or likely pathogenic variants, adjuvant olaparib after comp...